- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06057064
Study Will Assess the Safety, Neutralizing Activity and Efficacy of AZD3152 in Adults With Conditions Increasing Risk of Inadequate Protective Immune Response After Vaccination and Thus Are at High Risk of Developing Severe COVID-19 (NOVELLA)
A Phase II Randomized, Double-blind Study to Evaluate the Safety, Neutralizing Activity and Efficacy of AZD3152 for Pre-exposure Prophylaxis of COVID-19 in Participants Having an Increased Risk for Inadequate Response to Active Immunization (NOVELLA)
AZD3152, a single mAb, is being developed to have broad neutralizing activity across known SARS-CoV-2 variants of concern for pre-exposure prophylaxis of COVID-19.
The aim of the Phase II study is to evaluate the safety, neutralizing activity and efficacy of AZD3152 for pre exposure prophylaxis of COVID-19
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: AstraZeneca Clinical Study Information Center
- Phone Number: 1-877-240-9479
- Email: information.center@astrazeneca.com
Study Locations
-
-
-
Moscow, Russian Federation, 115478
- Research Site
-
Moscow, Russian Federation, 115522
- Research Site
-
Moscow, Russian Federation, 125284
- Research Site
-
Moscow, Russian Federation, 123182
- Research Site
-
Moscow, Russian Federation, 142770
- Research Site
-
St Petersburg, Russian Federation, 197341
- Research Site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Participant must be 18 years of age or older at the time of signing the informed consent.
- Weight ≥ 45 kg at Visit 1.
Participants must satisfy at least 1 of the following risk factors at enrollment:
- Obese, ie, BMI ≥ 30
- Congestive heart failure
- Chronic obstructive pulmonary disease
- Chronic kidney disease
- Intolerant of vaccine
Immunocompromised state (one of the following risk factors ):
- Have cancer
- Have solid organ transplant or a hematopoietic stem cell transplant
- Are actively taking immunosuppressive medicines
- Received chimeric antigen receptor T-cell therapy
- Within 1 year of receiving B-cell depleting therapies
- Have a moderate or severe primary immunodeficiency
- Medically stable
- WOCBP must not be pregnant or lactating and must use a highly effective method of contraception
Exclusion Criteria:
- Known hypersensitivity to any component of the study intervention
- Previous hypersensitivity or severe adverse reaction following administration of a mAb
- Acute or febrile infection prior to dosing
- Has HIV infection
- Receipt of any convalescent COVID-19 plasma treatment, mAb against SARS-CoV-2 , COVID-19 vaccine within 6 months
- COVID-19 antiviral prophylaxis within at least 2 weeks
- COVID-19 case within 6 months
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
Single dose of Placebo IM (0.9% sodium chloride)
|
Single dose of Placebo IM (0.9% sodium chloride)
|
Experimental: AZD3152
Single dose of 300 mg IM
|
300 mg single dose of AZD3152 IM
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The number and proportion of subjects with AEs, SAEs, MAAEs, AESIs.
Time Frame: up to Day 181
|
The safety profile will be evaluated using vital signs, laboratory data, electrocardiograms (ECGs), and adverse event data
|
up to Day 181
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Geometric mean titer (GMT) and geometric mean fold rise (GMFRs)
Time Frame: up to Day 181
|
NAbs response will be evaluated based on nAbs titer to the SARS-CoV-2 emerging dominant variant(s) circulating during the course of the study
|
up to Day 181
|
incidence of a post-treatment symptomatic COVID-19 case
Time Frame: up to Day 181
|
Incidence of a post-treatment symptomatic COVID-19 case (negative RT-PCR at baseline to positive RT-PCR or positive antigen test at any time up to 6 months AND symptoms specified in the modified WHO definition of symptomatic COVID-19).
|
up to Day 181
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The incidence of COVID-19 related hospitalization, and COVID-19 related death
Time Frame: up to 181 Day
|
The number and proportion of subjects diagnosed with COVID-19 with following events:
|
up to 181 Day
|
Incidence and percent of subjects with post treatment sero-response for SARS-CoV-2 nucleocapsid antibodies
Time Frame: up to 181 Day
|
Occurrence of post-treatment seroresponse (negative at baseline to positive at any time post-baseline up to 6 months) for SARS-CoV-2 nucleocapsid antibodies.
|
up to 181 Day
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- AZ-RU-00002
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on COVID-19, SARS-CoV-2
-
AstraZenecaActive, not recruitingCOVID-19, SARS-CoV-2Japan
-
University of Wisconsin, MadisonNational Institutes of Health (NIH)Completed
-
Syneos HealthUS Specialty Formulations, LLCCompletedSARS-CoV-2 (COVID-19)New Zealand
-
Mayo ClinicCompletedCOVID-19 | SARS-CoV 2United States
-
St. Olavs HospitalThe Research Council of Norway; Helse Nord-Trøndelag HF; Alesund Hospital; Namsos... and other collaboratorsCompletedSARS-CoV-2 Acute Respiratory Disease | SARS-CoV-2 Sepsis | SARS CoV 2 InfectionNorway
-
Boston UniversityNational Institute of Allergy and Infectious Diseases (NIAID); Burnet Institute and other collaboratorsRecruitingSARS CoV 2 Infection | SARS CoV 2 VaccinationUnited States, Malawi
-
University of MelbourneThe George Institute; The University of Queensland; The Peter Doherty Institute... and other collaboratorsRecruitingSARS-CoV-2 Infection (COVID-19)Australia
-
Medical University InnsbruckRecruitingSARS-CoV-2 | Post-acute COVID-19 SyndromeAustria
-
Stanford UniversityPfizerCompletedLong COVID | Post-acute Sequelae of SARS-CoV-2 InfectionUnited States
-
The Board of MedicineApollo Neuroscience, Inc.RecruitingPost-acute Sequelae of SARS-COV-2 InfectionUnited States
Clinical Trials on Biological: Placebo
-
Hoffmann-La RocheCompleted
-
Istituto Ortopedico RizzoliCompleted
-
ModernaTX, Inc.Biomedical Advanced Research and Development AuthorityCompleted
-
Assistance Publique - Hôpitaux de ParisNot yet recruitingBrain Tumor | Brain Lesion (General)France
-
Clinica Universidad de Navarra, Universidad de...Hospital General Universitario Gregorio Marañon; Hospital Clinic of Barcelona; Complejo Hospitalario de Navarra and other collaboratorsCompleted
-
Assistance Publique - Hôpitaux de ParisNot yet recruiting
-
BioNTech SEPfizerCompletedSARS-CoV-2 Infection, COVID-19United States, Spain, Finland, Poland, Mexico, Brazil
-
Centre Hospitalier Universitaire de NīmesCompleted
-
Centre Hospitalier Sud FrancilienCompletedFungal Infection | Bronchopulmonary Dysplasia | Extreme PrematurityFrance
-
University Hospital, ToursRecruitingAcute Lymphoid Leukemia | Acute Myeloid Leukemia in ChildrenFrance